Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.
| Ticker |
ANIX
|
| CIK | 0000715446 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?Here is how ANIXA BIOSCIENCES INC (ANIX) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year. Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine TechnologyAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2), a promising target ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out. Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year. Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical TrialAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt") under the direction of Dr. Robert Wenham, |